Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of switching suppressed adults with HIV-1 to lenacapavir + teropavimab + zinlirvimab twice yearly
2025-524336-19-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Aug 2026
- Modality
- Small Molecules, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of lenacapavir, Teropavimab and zinlirvimab in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of participants with HIV-1 RNA at least 50 copies/mL at Week 52. Planned start Aug 2026; status: authorised.
02
Drugs
lenacapavirTeropavimabzinlirvimab
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2025-524336-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524336-19-00.